Companies in #Autoimmune Disease

Allogene Therapeutics (NASDAQ: ALLO) is a clinical-stage biotechnology company headquartered in South San Francisco, California, pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease. Allogene's lead clinical programs include cemacabtagene ansegedleucel (cema-cel, ALLO-501A) for relapsed/refractory large B-cell lymphoma and the ALPHA3 trial of ALLO-329 (a CD19/CD70 dual-allogeneic CAR T) in autoimmune disease. The company was founded in 2017 by acquiring Pfizer's allogeneic CAR-T portfolio and is led by CEO Dr. Zach Roberts as of June 30, 2026.

Antares Therapeutics is a clinical-stage small molecule biopharmaceutical company developing oral and injectable therapies for autoimmune and inflammatory diseases. The company is headquartered in Princeton, New Jersey, and was acquired by Novartis in 2026.

Oblenio Bio is a biotechnology company developing trispecific T-cell engager (TCE) therapies for autoimmune diseases. The company raised a $62M Series B led by Pfizer Ventures in 2026 to advance its lead candidate LBL-051, a trispecific TCE targeting BCMA, CD19, and CD20 for B-cell driven autoimmune disorders.